Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 73, Issue 8

Molecular typing of reduced susceptibility of complex to Chlorhexidine in Turkey by pulsed-field gel electrophoresis No Access

Abstract

. The global spread of spp., particularly the (ACB) complex, has led to its recognition as a significant pathogen by the World Health Organization (WHO). The increasing resistance of the ACB complex to multiple antibiotics presents a challenge for treatment, necessitating accurate antibiotic susceptibility profiling after isolation.

. There is limited understanding of the antimicrobial resistance and chlorhexidine, a biocide, susceptibility profiles of ACB complex strains, especially in clinical settings in Turkey.

. This study aimed to identify ACB complex strains recovered from various clinical specimens at Hacettepe University Hospitals in Ankara, Turkey, in 2019, and to assess identification, their antibiotic and chlorhexidine susceptibility profiles, and genomic relatedness.

. Eighty-two ACB complex strains were identified using MALDI-TOF MS. Susceptibility testing to 12 antibiotics was conducted using the disc diffusion method, and colistin, chlorhexidine susceptibility was assessed using the broth microdilution technique, following the latest EUCAST and CLSI guidelines. ACB complex members with reduced chlorhexidine sensitivity were further analyzed by pulsed-field gel electrophoresis (PFGE) for bacterial typing.

. Among the isolates, 1.2% were multidrug-resistant (MDR), 73.2% were extensively drug-resistant (XDR), and 12.2% were pandrug-resistant (PDR). Carbapenem resistance was found in 86.7% of MDR, PDR, and XDR strains. Colistin resistance was observed in 15.8% of isolates, and 18.2% exhibited decreased susceptibility to chlorhexidine. PFGE revealed seven different clones among strains with reduced chlorhexidine sensitivity, indicating vertical transmission within the hospital.

. This study highlights the reduced susceptibility to chlorhexidine in ACB complex members and provides epidemiological insights into their spread. The findings underscore the importance of screening for antimicrobial resistance and biocide susceptibility profiles to effectively manage healthcare-associated infections.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): Acinetobacter , antibiotic resistance , chlorhexidine , colistin and PFGE
Funding
This study was supported by the:
  • Hacettepe Üniversitesi (Award THD-2019-18475.)
    • Principal Award Recipient: AbdullahTozluyurt
© 2024 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001882
2024-08-29
2025-12-10

Metrics

Loading full text...

Full text loading...

References

  1. Aygün G, Demirkiran O, Utku T, Mete B, Urkmez S et al. Environmental contamination during a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. J Hosp Infect 2002; 52:259–262 [View Article] [PubMed]
     [Google Scholar]
  2. Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, Aldabó-Pallás T, Cayuela A et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31:649–655 [View Article] [PubMed]
     [Google Scholar]
  3. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011; 11:355–362 [View Article] [PubMed]
     [Google Scholar]
  4. Wise MG, Karlowsky JA, Mohamed N, Hermsen ED, Kamat S et al. Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018-2022. J Glob Antimicrob Resist 2024; 37:168–175 [View Article] [PubMed]
     [Google Scholar]
  5. Villalón P, Ortega M, Sáez-Nieto JA, Carrasco G, Medina-Pascual MJ et al. Dynamics of a sporadic nosocomial Acinetobacter calcoaceticus–Acinetobacter baumannii complex population. Front Microbiol 2019; 10:593 [View Article] [PubMed]
     [Google Scholar]
  6. Blanco N, Harris AD, Rock C, Johnson JK, Pineles L et al. Risk factors and outcomes associated with multidrug-resistant Acinetobacter baumannii upon intensive care unit admission. Antimicrob Agents Chemother 2018; 62:01631 [View Article]
     [Google Scholar]
  7. Koeleman JG, Parlevliet GA, Dijkshoorn L, Savelkoul PH, Vandenbroucke-Grauls CM. Nosocomial outbreak of multi-resistant Acinetobacter baumannii on a surgical ward: epidemiology and risk factors for acquisition. J Hosp Infect 1997; 37:113–123 [View Article] [PubMed]
     [Google Scholar]
  8. Mah MW, Memish ZA, Cunningham G, Bannatyne RM. Outbreak of Acinetobacter baumannii in an intensive care unit associated with tracheostomy. Am J Infect Control 2001; 29:284–288 [View Article] [PubMed]
     [Google Scholar]
  9. Jang T-N, Lee S-H, Huang C-H, Lee C-L, Chen W-Y. Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control study. J Hosp Infect 2009; 73:143–150 [View Article] [PubMed]
     [Google Scholar]
  10. Mathai E, Mathai M, Schramm M, Baravilala W. Distribution and in vitro antimicrobial susceptibility of Acinetobacter species on the skin of healthy humans. Natl Med J India 2001; 14:
     [Google Scholar]
  11. Bartal C, Rolston KVI, Nesher L. Carbapenem-resistant Acinetobacter baumannii: colonization, infection and current treatment options. Infect Dis Ther 2022; 11:683–694 [View Article] [PubMed]
     [Google Scholar]
  12. Fitzpatrick MA, Ozer EA, Hauser AR. Utility of whole-genome sequencing in characterizing Acinetobacter epidemiology and analyzing hospital outbreaks. J Clin Microbiol 2016; 54:593–612 [View Article] [PubMed]
     [Google Scholar]
  13. Alvarez-Buylla A, Culebras E, Picazo JJ. Identification of Acinetobacter baumannii species: is Bruker biotyper MALDI-TOF mass spectrometry a good alternative to molecular techniques?. Infect Genet Evol 2012; 12:345–349 [View Article] [PubMed]
     [Google Scholar]
  14. Dortet L, Bonnin RA, Pennisi I, Gauthier L, Jousset AB et al. Rapid detection and discrimination of chromosome- and MCR-plasmid-mediated resistance to polymyxins by MALDI-TOF MS in Escherichia coli: the MALDIxin test. J Antimicrob Chemother 2018; 73:3359–3367 [View Article] [PubMed]
     [Google Scholar]
  15. Abdul-Mutakabbir JC, Griffith NC, Shields RK, Tverdek FP, Escobar ZK. Contemporary perspective on the treatment of Acinetobacter baumannii infections: insights from the society of infectious diseases pharmacists. Infect Dis Ther 2021; 10:1–26 [View Article] [PubMed]
     [Google Scholar]
  16. Balagopal S, Arjunkumar R. Chlorhexidine: the gold standard antiplaque agent. J Pharm sci Res 2013; 5:270
     [Google Scholar]
  17. Noor S. Chlorhexidine: its properties and effects. Res J Pharm Technol 2016; 9:1755–1760 [View Article]
     [Google Scholar]
  18. Karpiński TM, Szkaradkiewicz AK. Chlorhexidine--pharmaco-biological activity and application. Eur Rev Med Pharmacol Sci 2015; 19:1321–1326 [PubMed]
     [Google Scholar]
  19. Hashemi MM, Holden BS, Coburn J, Taylor MF, Weber S et al. Proteomic analysis of resistance of Gram-negative bacteria to chlorhexidine and impacts on susceptibility to colistin, antimicrobial peptides, and ceragenins. Front Microbiol 2019; 10:210 [View Article] [PubMed]
     [Google Scholar]
  20. Wand ME, Bock LJ, Bonney LC, Sutton JM. Mechanisms of increased resistance to chlorhexidine and cross-resistance to colistin following exposure of Klebsiella pneumoniae clinical isolates to chlorhexidine. Antimicrob Agents Chemother 2017; 61:01162 [View Article]
     [Google Scholar]
  21. Zhang Y, Zhao Y, Xu C, Zhang X, Li J et al. Chlorhexidine exposure of clinical Klebsiella pneumoniae strains leads to acquired resistance to this disinfectant and to colistin. Int J Antimicrob Agents 2019; 53:864–867 [View Article] [PubMed]
     [Google Scholar]
  22. Espinal P, Seifert H, Dijkshoorn L, Vila J, Roca I. Rapid and accurate identification of genomic species from the Acinetobacter baumannii (Ab) group by MALDI-TOF MS. Clin Microbiol Infect 2012; 18:1097–1103 [View Article] [PubMed]
     [Google Scholar]
  23. Lin F, Xu Y, Chang Y, Liu C, Jia X et al. Molecular characterization of reduced susceptibility to biocides in clinical isolates of Acinetobacter baumannii. Front Microbiol 2017; 8:1836 [View Article] [PubMed]
     [Google Scholar]
  24. Mohammadi Bardbari A, Mohajeri P, Arabestani MR, Karami M, Keramat F et al. Molecular typing of multi-drug resistant Acinetobacter baumannii isolates from clinical and environmental specimens in three Iranian hospitals by pulsed field gel electrophoresis. BMC Microbiol 2020; 20:1–7 [View Article] [PubMed]
     [Google Scholar]
  25. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33:2233–2239 [View Article] [PubMed]
     [Google Scholar]
  26. Smet A, Boyen F, Pasmans F, Butaye P, Martens A et al. OXA-23-producing Acinetobacter species from horses: a public health hazard?. J Antimicrob Chemother 2012; 67:3009–3010 [View Article] [PubMed]
     [Google Scholar]
  27. Mea HJ, Yong PVC, Wong EH. An overview of Acinetobacter baumannii pathogenesis: motility, adherence and biofilm formation. Microbiol Res 2021; 247:126722 [View Article] [PubMed]
     [Google Scholar]
  28. Wang SH, Sheng WH, Chang YY, Wang LH, Lin HC et al. Healthcare-associated outbreak due to pan-drug resistant Acinetobacter baumannii in a surgical intensive care unit. J Hosp Infect 2003; 53:97–102 [View Article] [PubMed]
     [Google Scholar]
  29. Amar AK, Sawant AR, Manoharan M, Tomar A, Sistla S et al. Genome sequences of bla NDM-1 producing Acinetobacter lactucae isolated from immunocompromised patients in India. Microbiol Resour Announc 2023; 12:e00220-23
     [Google Scholar]
  30. Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS et al. Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diagn Microbiol Infect Dis 2012; 73:267–270 [View Article] [PubMed]
     [Google Scholar]
  31. Gülen TA, Ayfer İ, Ö İ, K Ü. Acinetobacter baumannii infections and antibiotic resistance in hospitalized patients in an education and research hospital: a six-year analysis. Flora 2021; 25:
     [Google Scholar]
  32. Worku S, Abebe T, Seyoum B, Alemu B, Denkayehu G et al. Molecular characterization of carbapenemase and extended spectrum beta-lactamase producing Acinetobacter baumannii isolates causing surgical site infections in Ethiopia. BMC Infect Dis 2024; 24:459 [View Article] [PubMed]
     [Google Scholar]
  33. Maraki S, Mantadakis E, Mavromanolaki VE, Kofteridis DP, Samonis G. A 5-year surveillance study on antimicrobial resistance of Acinetobacter baumannii clinical isolates from a tertiary Greek hospital. Infect Chemother 2016; 48:190 [View Article]
     [Google Scholar]
  34. Abarca-Coloma L, Puga-Tejada M, Nuñez-Quezada T, Gómez-Cruz O, Mawyin-Muñoz C et al. Risk factors associated with mortality in Acinetobacter baumannii infections: results of a prospective cohort study in a Tertiary Public Hospital in Guayaquil, Ecuador. Antibiotics (Basel) 2024; 13:213 [View Article] [PubMed]
     [Google Scholar]
  35. Lob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents 2016; 47:317–323 [View Article] [PubMed]
     [Google Scholar]
  36. Chen F-J, Huang W-C, Liao Y-C, Wang H-Y, Lai J-F et al. Molecular epidemiology of emerging carbapenem resistance in Acinetobacter nosocomialis and Acinetobacter pittii in Taiwan, 2010 to 2014. Antimicrob Agents Chemother 2019; 63:02007-18 [View Article]
     [Google Scholar]
  37. Yang J, Chen Y, Jia X, Luo Y, Song Q et al. Dissemination and characterization of NDM-1-producing Acinetobacter pittii in an intensive care unit in China. Clin Microbiol Infect 2012; 18:E506–E513 [View Article] [PubMed]
     [Google Scholar]
  38. Fu Y, Jiang J, Zhou H, Jiang Y, Fu Y et al. Characterization of a novel plasmid type and various genetic contexts of bla OXA-58 in Acinetobacter spp. from multiple cities in China. PLoS One 2014; 9:e84680 [View Article]
     [Google Scholar]
  39. Singkham-In U, Chatsuwan T. Mechanisms of carbapenem resistance in Acinetobacter pittii and Acinetobacter nosocomialis isolates from Thailand. J Med Microbiol 2018; 67:1667–1672 [View Article] [PubMed]
     [Google Scholar]
  40. Vakili B, Fazeli H, Shoaei P, Yaran M, Ataei B et al. Detection of colistin sensitivity in clinical isolates of Acinetobacter baumannii in Iran. J Res Med Sci 2014; 19:S67 [PubMed]
     [Google Scholar]
  41. Hameed F, Khan MA, Muhammad H, Sarwar T, Bilal H et al. Plasmid-mediated mcr-1 gene in Acinetobacter baumannii and Pseudomonas aeruginosa: first report from Pakistan. Rev Soc Bras Med Trop 2019; 52:e20190237 [View Article] [PubMed]
     [Google Scholar]
  42. Lima WG, Brito JCM, Cardoso BG, Cardoso VN, de Paiva MC et al. Rate of polymyxin resistance among Acinetobacter baumannii recovered from hospitalized patients: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2020; 39:1427–1438 [View Article]
     [Google Scholar]
  43. Gall E, Long A, Hall KK. Chlorhexidine bathing strategies for multidrug-resistant organisms: a summary of recent evidence. J Patient Saf 2020; 16:S16–S22 [View Article] [PubMed]
     [Google Scholar]
  44. Suwantarat N, Carroll KC, Tekle T, Ross T, Maragakis LL et al. High prevalence of reduced chlorhexidine susceptibility in organisms causing central line–associated bloodstream infections. Infect Control Hosp Epidemiol 2014; 35:1183–1186 [View Article]
     [Google Scholar]
  45. Russell AD, Tattawasart U, Maillard J-Y, Furr JR. Possible link between bacterial resistance and use of antibiotics and biocides. Antimicrob Agents Chemother 1998; 42:2151 [View Article]
     [Google Scholar]
  46. Royer G, Poirel L, La Combe B, Clermont O, Chau F et al. Lack of association between colistin resistance and chlorhexidine reduced susceptibility in clinical isolates of Escherichia coli. J Antimicrob Chemother 2021; 76:2736–2737 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001882
Loading
Molecular typing of reduced susceptibility of Acinetobacter calcoaceticus–baumannii complex to Chlorhexidine in Turkey by pulsed-field gel electrophoresis
J. Med. Microbiol. 73, 001882 (2024); https://doi.org/10.1099/jmm.0.001882
/content/journal/jmm/10.1099/jmm.0.001882
/content/journal/jmm/10.1099/jmm.0.001882
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Supplementary material 2

EXCEL

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error